# Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT01794520** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 117 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01794520
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-10
- **Primary completion:** 2021-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2023-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794520, "Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01794520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*